Filters: Keyword is Narcotic Antagonists [Clear All Filters]
"Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone." Journal of addiction medicine 6, no. 4 (2012): 274-9. Abstract
"Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial." Addictive behaviors 35, no. 5 (2010): 537-40. Abstract
"A trial of integrated buprenorphine/naloxone and HIV clinical care." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S184-90. Abstract
"Treatment of adolescent opioid dependence: no quick fix." JAMA : the journal of the American Medical Association 300, no. 17 (2008): 2057-9.
"Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone." The American journal of drug and alcohol abuse 37, no. 4 (2011): 224-8. Abstract
"Substance use of disorders in HIV-infected patients: impact and new treatment strategies." Topics in HIV medicine : a publication of the International AIDS Society, USA 12, no. 3 (2004): 77-82. Abstract
"Social and structural aspects of the overdose risk environment in St. Petersburg, Russia." The International journal on drug policy 20, no. 3 (2009): 270-6. Abstract
"Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients." Drug and alcohol dependence 118, no. 2-3 (2011): 326-34. Abstract
"A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain." Addictive behaviors 33, no. 1 (2008): 173-9. Abstract
"The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?" Drug and alcohol dependence 79, no. 1 (2005): 113-6. Abstract
"The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S178-83. Abstract
"Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone." Drug and alcohol dependence 105, no. 3 (2009): 234-9. Abstract
"Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence." The American journal of drug and alcohol abuse 37, no. 1 (2011): 1-11. Abstract
"Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S14-21. Abstract
"Opioid dependence: rationale for and efficacy of existing and new treatments." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S173-7. Abstract
"Opioid Dependence Treatment in the Emergency Department--Reply." JAMA 314, no. 8 (2015): 835.
"Narrative review: buprenorphine for opioid-dependent patients in office practice." Annals of internal medicine 148, no. 9 (2008): 662-70. Abstract
"Models for integrating buprenorphine therapy into the primary HIV care setting." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 42, no. 5 (2006): 716-21. Abstract
"Medical interventions for addictions in the primary care setting." Topics in HIV medicine : a publication of the International AIDS Society, USA 18, no. 1 (2010): 8-12. Abstract
"Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial." Lancet 371, no. 9631 (2008): 2192-200. Abstract
"Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 17, no. 2 (2008): 116-20. Abstract
"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market." The American journal of drug and alcohol abuse 35, no. 2 (2009): 68-72. Abstract
"Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S235-46. Abstract
"Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S224-34. Abstract
"Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S68-75. Abstract
"Integration of buprenorphine for substance-abuse treatment by HIV care providers." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S1-2.
"Initial strategies for integrating buprenorphine into HIV care settings in the United States." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S191-6. Abstract
"Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S83-90. Abstract
"Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S39-45. Abstract
"Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment." Journal of urban health : bulletin of the New York Academy of Medicine 87, no. 4 (2010): 592-602. Abstract
"The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S54-61. Abstract
"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S22-32. Abstract
"HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications." The International journal on drug policy 18, no. 4 (2007): 326-8. Abstract
"HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment." Journal of addiction medicine 7, no. 6 (2013): 410-6. Abstract
"Heroin dependence and HIV infection in Malaysia." Drug and alcohol dependence 82 Suppl 1 (2006): S39-42. Abstract
"Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone." Alcoholism, clinical and experimental research 36, no. 2 (2012): 318-24. Abstract
"Factors affecting willingness to provide buprenorphine treatment." Journal of substance abuse treatment 36, no. 3 (2009): 244-51. Abstract
"Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality." American journal of public health 99, no. 3 (2009): 402-7. Abstract
"Effectiveness and feasibility study of routine HIV rapid testing in an urban methadone maintenance treatment program." The American journal of drug and alcohol abuse 39, no. 4 (2013): 247-51. Abstract
"Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S33-8. Abstract
"Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States." Addiction (Abingdon, England) 103, no. 6 (2008): 979-89. Abstract
"Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users." Addiction (Abingdon, England) 100, no. 2 (2005): 150-8. Abstract
"Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals." Drugs 72, no. 2 (2012): 217-28. Abstract
"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence." The New England journal of medicine 355, no. 4 (2006): 365-74. Abstract
"The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S76-82. Abstract
"Cost and utilization outcomes of opioid-dependence treatments." The American journal of managed care 17 Suppl 8 (2011): S235-48. Abstract
"Coordination of medical care and opioid dependence treatment in primary care: a case report." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 24, no. 1 (2003): 43-6.
"Consensus statement on office-based treatment of opioid dependence using buprenorphine." Journal of substance abuse treatment 27, no. 2 (2004): 153-9. Abstract
"Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial." Annals of internal medicine 152, no. 11 (2010): 704-11. Abstract
"Changing law from barrier to facilitator of opioid overdose prevention." The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 41 Suppl 1 (2013): 33-6. Abstract
